Gut Microbiota Market Size & Share, by Product (Probiotics, Prebiotics, Supplements, Drugs, Foods); Application (Therapeutics, Diagnostics); Disease (Autoimmune Disorder, Gastrointestinal Disorder, Infectious) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3251
  • Published Date: Apr 04, 2023
  • Report Format: PDF, PPT

Companies Dominating the Gut Microbiota Landscape

    • Merck KGaA
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Metabiomics Corporation
    • ViThera Pharmaceuticals, Inc.
    • Second Genome Inc.
    • Microbiome Therapeutics LLC
    • Vedanta Biosciences, Inc.
    • Osel, Inc.
    • Synthetic Biologics, Inc.
    • Synlogic
    • 4D Pharma plc
    • Metabogen AB
    • Symbiotix Biotherapies, Inc.

Browse Key Market Insights with Data Illustration:


In The News

  • Merck KGaA a leading science and technology company and leader in genome editing, collaborated with Washington University in St. Louis, Missouri, USA, for leading towards the optimization of nutritional supplements to restore a healthy gut microbial community (microbiome). This gut bacteria research would use Merck’s genome-editing technology and may lead to diagnostics, and treatment for malnourished children.

  • Metabiomics Corp., an early-stage molecular diagnostics company entered into a joint venture with Prescient Medicine Holdings, LLC, a company that operates in the Medical Devices industry to develop an innovative microbiome diagnostics platform. This platform will detect precancerous colon polyps and diagnose other types of gastrointestinal diseases including Crohn’s, colitis (IBD), and irritable bowel syndrome (IBS).

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 3251
  • Published Date: Apr 04, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The increasing focus on gut health and the immunity system post-pandemic as well as the rising prevalence of digestive illness coupled with chronic diseases are the major factors driving the market growth.

The market size of gut microbiota is anticipated to attain a CAGR of ~20% over the forecast period, i.e., 2023-2035.

Lack of funds, technology, and infrastructures are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Merck KGaA, Metabiomics Corp., ViThera Pharmaceuticals, Inc., Second Genome Inc., Microbiome Therapeutics LLC, Vedanta Biosciences, Inc., and Osel, Inc.

The company profiles are selected on the basis of revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by product, application, disease, and by region.

The therapeutics segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying